Literature DB >> 10698152

Good or evil: CD26 and HIV infection.

T Ohtsuki1, H Tsuda, C Morimoto.   

Abstract

Acquired immune deficiency syndrome (AIDS) is an incurable disease at present and so many efforts to conquer this disease are being made around the world. In studies of human immunodeficiency virus (HIV) infection and the disease progression, it has been reported that T cells expressing CD26 are preferentially infected and depleted in HIV-infected individuals. CD26 is a widely distributed 110 kDa cell-surface glycoprotein with known dipeptidyl peptidase IV (DPPIV) activity in its extracellular domain. This ectoenzyme is capable of cleaving N-terminal dipeptides from polypeptides with either proline or alanine residues in the penultimate position. On human T cells, CD26 exhibits the co-stimulatory function and plays an important role in immune response via its ability to bind adenosine deaminase (ADA) and association with CD45. Recent studies have been stripping the veil from over the relationship between CD26 and HIV infection. Susceptibility of cells to HIV infection is correlated with CD26 expression, and HIV transactivator Tat and envelope protein gp120 are reported to interact with CD26. These observations indicate that CD26 is closely involved in HIV cell entry and that CD26-mediated T cell immune response is suppressed. In addition, it has been demonstrated that the anti-HIV and chemotactic activities of RANTES (regulated on activation, normal T cell expressed and secreted) and stromal cell-derived factor-1 (SDF-1) are controlled with the DPPIV activity of CD26. Thus, the regulation of the function of chemokines by CD26/DPPIV appears to be essential for lymphocyte trafficking and infectivity of HIV strains.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698152     DOI: 10.1016/s0923-1811(99)00081-x

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  10 in total

Review 1.  Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.

Authors:  Andrew W Woodham; Joseph G Skeate; Adriana M Sanna; Julia R Taylor; Diane M Da Silva; Paula M Cannon; W Martin Kast
Journal:  AIDS Patient Care STDS       Date:  2016-07       Impact factor: 5.078

2.  The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells.

Authors:  Emilie C Lefort; Jonathan Blay
Journal:  Clin Exp Metastasis       Date:  2011-02-05       Impact factor: 5.150

3.  Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study.

Authors:  Scott R Goodwin; Dominic N Reeds; Michael Royal; Heidi Struthers; Erin Laciny; Kevin E Yarasheski
Journal:  J Clin Endocrinol Metab       Date:  2012-12-21       Impact factor: 5.958

4.  Interaction of human dipeptidyl peptidase IV and human immunodeficiency virus type-1 transcription transactivator in Sf9 cells.

Authors:  Felista L Tansi; Véronique Blanchard; Markus Berger; Rudolf Tauber; Werner Reutter; Hua Fan
Journal:  Virol J       Date:  2010-10-13       Impact factor: 4.099

5.  CD26/dipeptidyl peptidase IV (CD26/DPPIV) is highly expressed in peripheral blood of HIV-1 exposed uninfected female sex workers.

Authors:  Elijah M Songok; Bernard Osero; Lyle McKinnon; Martin K Rono; Winnie Apidi; Elizabeth J Matey; Adrienne F A Meyers; Ma Luo; Joshua Kimani; Charles Wachihi; Blake T Ball; Frank A Plummer; Solomon Mpoke
Journal:  Virol J       Date:  2010-11-25       Impact factor: 4.099

6.  New insights into the possible role of bacteriophages in host defense and disease.

Authors:  Andrzej Gorski; Krystyna Dabrowska; Kinga Switala-Jeleń; Maria Nowaczyk; Beata Weber-Dabrowska; Janusz Boratynski; Joanna Wietrzyk; Adam Opolski
Journal:  Med Immunol       Date:  2003-02-14

Review 7.  The nonglycemic actions of dipeptidyl peptidase-4 inhibitors.

Authors:  Na-Hyung Kim; Taeyang Yu; Dae Ho Lee
Journal:  Biomed Res Int       Date:  2014-07-21       Impact factor: 3.411

8.  Delayed allogeneic skin graft rejection in CD26-deficient mice.

Authors:  Xiangli Zhao; Kai Zhang; Peter Daniel; Natali Wisbrun; Hendrik Fuchs; Hua Fan
Journal:  Cell Mol Immunol       Date:  2018-03-23       Impact factor: 11.530

9.  Integration of microarray data and literature mining identifies a sex bias in DPP4+CD4+ T cells in HIV-1 infection.

Authors:  Hans Christian Stubbe; Christine Dahlke; Katharina Rotheneder; Renate Stirner; Julia Roider; Raffaele Conca; Ulrich Seybold; Johannes Bogner; Marylyn Martina Addo; Rika Draenert
Journal:  PLoS One       Date:  2020-09-18       Impact factor: 3.240

Review 10.  CD26 and Asthma: a Comprehensive Review.

Authors:  Juan J Nieto-Fontarigo; Francisco J González-Barcala; Esther San José; Pilar Arias; Montserrat Nogueira; Francisco J Salgado
Journal:  Clin Rev Allergy Immunol       Date:  2019-04       Impact factor: 8.667

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.